Lung cancer varies widely from patient to patient, and that diversity makes it hard to find effective treatments. Researchers ...
Updated NCCN Clinical Practice Guidelines in Oncology now recognize that MammaPrint and BluePrint testing can help identify a ...
In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...
In vitro and in silico tools help drug developers reduce unwanted immunogenicity of biologics at the design stage. These include assays that examine different immune system processes leading to ...
Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...
Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...
Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States Translational Tissue Engineering Center, Johns Hopkins University School of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results